Profile data is unavailable for this security.
About the company
Hester Biosciences Limited is an India-based animal healthcare company. The Company is principally engaged in manufacturing poultry vaccines, large animal vaccines, and trading poultry, large animal, and petcare health products. Its segments include Poultry Healthcare, Animal Healthcare, and Others. The Poultry Healthcare vaccines include Gumboro I, Inactivated Chick ND, Inactivated Coryza, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IBD, among others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, PPR Vaccine - Sungri/96, among others. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet, Pawfresh, Synoton, Petsglow, Vitacoat, WormPeril, Hestaliv, TumOnzym and Safeline Spot. Its manufacturing facility is located at Village Meda-Adraj, Taluka Kadi, Mehsana District, Gujarat.
- Revenue in INR (TTM)3.14bn
- Net income in INR409.47m
- Incorporated1987
- Employees562.00
- LocationHester Biosciences LtdPushpak 1st FloorMotilal Hirabhai Road, Panchvati CircleAHMEDABAD 380006IndiaIND
- Phone+91 7 926445107
- Fax+91 7 926445105
- Websitehttps://www.hester.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wanbury Ltd | 6.58bn | 646.86m | 8.73bn | 1.38k | 13.07 | -- | 11.04 | 1.33 | 19.13 | 19.13 | 194.16 | -- | -- | -- | -- | 4,758,967.00 | -- | 8.87 | -- | 101.40 | 55.07 | 41.82 | 9.84 | 5.62 | -- | 2.97 | -- | -- | 4.15 | 10.29 | -45.44 | -13.88 | 44.32 | -- |
| Venus Remedies Ltd | 7.00bn | 762.95m | 9.36bn | 1.30k | 12.27 | -- | 9.37 | 1.34 | 57.10 | 57.10 | 523.77 | -- | -- | -- | -- | 5,391,957.00 | -- | 6.67 | -- | 8.08 | 47.02 | 37.62 | 10.90 | 6.87 | -- | 1,849.19 | -- | -- | 7.72 | 13.81 | 59.05 | -- | 18.36 | -- |
| Bajaj Healthcare Ltd | 6.12bn | 523.16m | 10.03bn | 904.00 | 19.67 | -- | 12.58 | 1.64 | 16.15 | 15.36 | 188.83 | -- | -- | -- | -- | 6,774,850.00 | -- | 7.07 | -- | 13.07 | 46.31 | 37.17 | 8.54 | 8.22 | -- | 2.92 | -- | 5.83 | 14.61 | 5.76 | 399.64 | 11.21 | -12.65 | -- |
| Beta Drugs Ltd | -100.00bn | -100.00bn | 10.82bn | 399.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 15.08 | -- | 21.53 | -- | 40.30 | -- | 12.72 | -- | -- | -- | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| Syncom Formulations (India) Ltd | 5.03bn | 689.58m | 11.34bn | 554.00 | 15.46 | -- | 15.26 | 2.26 | 0.78 | 0.78 | 5.58 | -- | -- | -- | -- | 9,072,854.00 | -- | 8.56 | -- | 11.58 | 40.05 | 34.81 | 13.72 | 10.15 | -- | 75.71 | -- | -- | 76.55 | 17.74 | 95.28 | 28.24 | 41.62 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.82bn | 409.03m | 11.39bn | 1.40k | 28.04 | -- | 22.63 | 4.04 | 6.07 | 6.07 | 41.76 | -- | -- | -- | -- | 2,012,738.00 | -- | 14.71 | -- | 17.26 | 63.66 | 60.59 | 14.53 | 12.54 | -- | 44.64 | -- | 39.88 | 28.76 | 11.13 | 146.45 | 47.72 | -28.44 | 65.72 |
| Sakar Healthcare Ltd | 2.31bn | 252.21m | 11.75bn | 342.00 | 46.11 | -- | 24.31 | 5.09 | 11.45 | 11.45 | 104.95 | -- | -- | -- | -- | 6,750,901.00 | -- | 4.73 | -- | 5.64 | 52.54 | 45.55 | 10.92 | 9.87 | -- | 3.66 | -- | -- | 15.80 | 16.44 | 49.96 | 12.71 | 19.34 | -- |
| IND Swift Laboratories Ltd | 9.64bn | 2.75bn | 11.90bn | 1.25k | 3.59 | -- | 3.70 | 1.23 | 38.28 | 38.28 | 122.91 | -- | -- | -- | -- | 7,738,014.00 | -- | 8.65 | -- | 10.59 | 51.55 | 40.96 | 28.56 | 14.35 | -- | -3.35 | -- | 0.00 | -56.15 | -6.35 | -40.50 | -- | 41.97 | -- |
| Lincoln Pharmaceuticals Ltd | 6.52bn | 878.34m | 12.48bn | 1.85k | 14.20 | -- | 12.25 | 1.91 | 43.86 | 43.86 | 325.55 | -- | -- | -- | -- | 3,518,272.00 | -- | 13.22 | -- | 15.46 | 53.64 | 50.82 | 13.47 | 14.56 | -- | 77.35 | -- | 3.32 | 7.35 | 10.03 | -11.74 | 9.87 | 20.13 | -- |
| Hester Biosciences Ltd | 3.14bn | 409.47m | 12.84bn | 562.00 | 40.05 | -- | 21.54 | 4.08 | 37.69 | 37.69 | 277.25 | -- | -- | -- | -- | 5,594,555.00 | -- | 5.39 | -- | 6.72 | 73.52 | 64.87 | 13.51 | 11.44 | -- | 9.65 | -- | 23.77 | 2.15 | 11.16 | 45.52 | -1.18 | -22.47 | 1.18 |
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 14.44bn | 456.00 | 40.81 | -- | 27.12 | 3.23 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Windlas Biotech Ltd | 8.68bn | 667.47m | 15.91bn | 1.35k | 24.00 | -- | 16.27 | 1.83 | 31.46 | 31.46 | 409.16 | -- | -- | -- | -- | 6,450,929.00 | -- | 8.65 | -- | 11.81 | 38.34 | 34.09 | 7.69 | 7.70 | -- | 15.80 | -- | 18.33 | 20.43 | 18.24 | 4.82 | 30.34 | 27.99 | -- |
| Amrutanjan Health Care Ltd | 4.88bn | 569.03m | 16.49bn | 631.00 | 28.99 | -- | 26.08 | 3.38 | 19.68 | 19.68 | 168.85 | -- | -- | -- | -- | 7,736,897.00 | -- | 15.84 | -- | 19.67 | 50.87 | 52.17 | 11.66 | 13.26 | -- | 319.69 | -- | 19.82 | 7.26 | 11.56 | 13.03 | 15.17 | 69.46 | 26.76 |
Data as of Mar 06 2026. Currency figures normalised to Hester Biosciences Ltd's reporting currency: Indian Rupee INR
0.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 34.32k | 0.40% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 3.28k | 0.04% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 748.00 | 0.01% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 516.00 | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Jan 2026 | 119.00 | 0.00% |
| DFA Australia Ltd.as of 30 Nov 2025 | 89.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 47.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 15 Feb 2026Source: FactSet Research Systems Inc.
